Foamix stock bub­bles high­er on lat­est ac­ne PhI­II; Con­cen­tric Anal­gesic gets an FDA 'break­through'

→ Shares of Foamix Ther­a­peu­tics $FOMX soared Tues­day night on news that their third Phase III study of a new ac­ne med suc­ceed­ed in de­liv­er­ing sig­nif­i­cant ben­e­fits. The num­bers may not be over­whelm­ing, with in­ves­ti­ga­tors not­ing that a “mean re­duc­tion in in­flam­ma­to­ry le­sion count at Week 12 rel­a­tive to base­line was -16.93 for the FMX101 treat­ment group and -13.40 for the ve­hi­cle treat­ment group (p<0.0001).” But in­vestors loved it. Shares rock­et­ed up more than 50% in af­ter-mar­ket trad­ing and were still up 23% in ear­ly morn­ing trad­ing Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.